Recent safety concerns with proton pump inhibitors

Journal of Clinical Gastroenterology

Volumn 46, Issue 2, 2012, Pages 93-114

  Chen, Joan ^a   Yuan, Yuhong Cathy ^b   Leontiadis, Grigorios I ^b   Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

clopidogrel; fractures; hypomagnesemia; proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CALCIUM CARBONATE; CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MAGNESIUM; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICAGRELOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7;

BEDTIME DOSAGE; BINDING SITE; BONE DENSITY; CARDIOVASCULAR DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIP FRACTURE; HUMAN; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; LONG TERM CARE; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MORNING DOSAGE; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VERTEBRA FRACTURE; WRIST FRACTURE;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FRACTURES, SPONTANEOUS; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERCALCIURIA; NEPHROCALCINOSIS; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL TUBULAR TRANSPORT, INBORN ERRORS; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84862908852     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182333820     Document Type: Review

References (150)

1. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260.
2. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038-1039.
3. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
4. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
5. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel MEDCO outcomes study. Pharmacotherapy. 2010;30:787-796.
6. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and plasugrel with or without a proton pump inhibitor: an analysis of two randomized trials. Lancet. 2009;374:989-997.
7. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152:337-345.
8. Howden CW. PPIs and clopidogrel: the band plays on. Am J Gastroenterol. 2010;105:2438-2439.
9. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103:2890-2907.
10. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/ AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105: 2533-2549.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
12. Fork FT, Lafolie P, Toth E, et al. Gastroduodenal tolerance of 75 mg clopidogrel versus 325mg aspirin in healthy volunteers: a gastroscopic study. Scand J Gastroenterol. 2000;35:464-469. (Pubitemid 30354084)
13. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol. 2010;105: 34-41.
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
15. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional nonaspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731-1738. (Pubitemid 44893570)
16. Ibanez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235-242. (Pubitemid 43382032)
17. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med. 2001;345: 494-502. (Pubitemid 32758501)
18. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
19. Laizure SC, Parker RB. A comparison of the metabolism of clopidogrel and prasugrel. Expert Opin Drug Metab Toxicol. 2010;6:1417-1424.
20. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispo. 2010;38:92-99.
21. Plavix label NDA 20-839 / S-044. http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/020839s044lbl.pdf (Accessed March 21, 2011).
22. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89:65-74.
23. Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627-638.
24. Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, andrabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. (Pubitemid 38955611)
25. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49: 509-533.
26. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009;120: 2310-2312.
27. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-1830.
28. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19. *2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134-143.
29. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplateleteffect and clinical efficacy of clopidogrel therapy. J Am Med Assoc. 2009;302:849-857.
30. Amoah V, Worrall AP, Smallwood A, et al. Clopidogrel and proton pump inhibitors: can near patient testing help in the tailoring of dual antiplatelet prescription? J Thromb Haemost. 2010;8:1422-1424.
31. Chyrchel B, Surdacki A, Chyrchel M, et al. Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy. Int J Cardiol. 2011;149:124-125.
32. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009;54:1149-1153.
33. Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv. 2010;3:436-441.
34. Fontes-Carvalho R, Albuquerque A, Araú jo C, et al. The clopidogrel-proton pump inhibitors' drug interaction is not a class effect: a randomized clinical study in patients after acute myocardial infarction under dual anti-platelet therapy [abstract OP006]. Gut. 2010;59(Suppl III):A2.
35. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010;70:383-392.
36. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol n the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508-2509. (Pubitemid 44575451)
37. Gremmel T, Steiner S, Seidinger D, et al. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56:532-539.
38. Hokimoto S, Ogawa H. Is it safe to use a proton pump inhibitor with clopidogrel? A comparison of clopidogrel with or without rabeprazole in Japan [abstract T1155]. Gastroenterology. 2010;138(5, Suppl 1):S498.
39. Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140:791-798.e2.
40. Hulot JS, Wuerzner G, Bachelot-Loza C, et al. Effect of an increased clopidogrel maintenance dose or lansoprazole coadministration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost. 2010;8:610-613.
41. Neubauer H, Engelhardt A, Krü ger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting. Cardiovasc Pharmacol. 2010;56:91-97.
42. Pasquali SK, Yow E, Jennings LK, et al. Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. Congenit Heart Dis. 2010;5:552-555.
43. Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009;103:1339-1343.
44. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-719.
45. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:e1-e5.
46. Siriswangvat S, Sansanayudh N, Nathisuwan S, et al. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J. 2010;74: 2187-2192.
47. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-484. (Pubitemid 351389118)
48. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456-1462.
49. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J. 2010;51: 13-16.
50. Zhang R, Ran HH, Zhu HL, et al. Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation. J Int Med Res. 2010;38:1617-1625.
51. Zuern CS, Geisler T, Lutilsky N, et al. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res. 2010;125:e51-e54.
52. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516. (Pubitemid 46517957)
53. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.
54. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4:542-549.
55. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drugeluting stent thrombosis. J Am Coll Cardiol. 2007;49: 2312-2317. (Pubitemid 46891710)
56. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003;59: 295-302. (Pubitemid 36792384)
57. Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011;107:871-878.
58. Bhatt DL, Cryer BL, Contant CF, et al. for the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917.
59. Chan A, Ng FH, Chang CM, et al. Prevalence and prediction of gastrointestinal events in patients receiving a combination of aspirin plus clopidogrel [abstract 916]. Gastroenterology. 2007;132(4 suppl 2):135.
60. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular riskindependent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153:378-386.
61. Cuschieri JR, Drawz P, Falck-Ytter Y, et al. Risk factors for acute gi bleeding following myocardial infarction in patients who are prescribed clopidogrel [abstract 108]. Gastroenterology. 2010;138(5, suppl 1):S-20.
62. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract 3999]. Circulation. 2008;118:S815.
63. Evanchan J, Donnally MR, Binkley P, et al. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33:168-171.
64. Gaglia MA Jr, Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol. 2010;105:833-838.
65. Gaspar A, Ribeiro S, Nabais S, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol. 2010;29:1511-1520.
66. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55:1964-1968.
67. Hsiao FY, Tsai YW, Huang WF, et al. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther. 2009;31:2038-2047.
68. Huang CC, Chen YC, Leu HB, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105:1705-1709.
69. Hudzik B, Szkodzinski J, Danikiewicz A, et al. Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-b1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Eur Cytokine Netw. 2010;21:257-263.
70. Joshi A, Bursey F, Connors S. GI cytoprotection after coronary stenting [abstract P0824]. Gut. 2009;58(Suppl II): A269.
71. Juurlink DN, Gomes T, Mamdani MM, et al. The safety of proton pump inhibitors and clopidogrel in patients after stroke. Stroke. 2011;42:128-132.
72. Lin KY, Hernandez-Diaz S, Garcia Rodriguez LA. Effect of anti-secretory medicines and nitrates on the risk of ulcer bleeding among users of clopidogrel, low-dose acetylsalicylic acid, corticosteroids, non-steroidal anti-inflammatory drugs, and oral anticoagulants [abstract 665]. Gastroenterology. 2010;138(5, suppl 1):S-90.
73. Luinstra M, Naunton M, Peterson GM, et al. PPI use in patients commenced on clopidogrel: a retrospective crosssectional evaluation. J Clin Pharm Ther. 2010;35:213-217.
74. Muñ oz-Torrero JF, Escudero D, Suá rez C, et al. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de riesgo y enfermedad arterial (FRENA) registry. J Cardiovasc Pharmacol. 2011;57:13-19.
75. Ng FH, Lam KF, Wong SY, et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008;77:173-177.
76. Ortolani P, Marino M, Marzocchi A, et al. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med (Hagerstown). 2011. [Epub ahead of print].
77. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120: 2322-2329.
78. Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf. 2010;19:848-857.
79. Rossini R, Capodanno D, Musumeci G, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis. 2011;22:199-205.
80. Sarafoff N, Sibbing D, Sonntag U, et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost. 2010;104:626-632.
81. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123:474-482.
82. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170:704-710.
83. Tentzeris I, Jarai R, Farhan S, et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211-1218.
84. Tsai YW, Wen YW, Huang WF, et al. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol. 2011;46:39-45.
85. Valkhoff VE, 't Jong GW, van Soest EM, et al. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther. 2011;33:77-88.
86. van Boxel OS, van Oijen MG, Hagenaars MP, et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010;105:2430-2436.
87. Wang SS, Tsai SS, Hsu PC, et al. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of reinfarction. Am J Gastroenterol. 2009;104:3116-3117.
88. Wu CY, Chan FK, Wu MS, et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology. 2010;139: 1165-1171.
89. Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26:e54-e57.
90. Siller-Matula JM, Jilma B, Schrö r K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2624-2641.
91. Ngamruengphong S, Leontiadis GI, Crowell MD, et al. Risk of adverse cardiovascular events with concomitant use of clopidogrel and proton pump inhibitors(PPI): systematic review and meta-analysis of observational studies [abstract T1078]. Gastroenterology. 2010;138(5, suppl 1):S-483.
92. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31:810-823.
93. Gerson LB, McMahon D, Olkin I, et al. Meta-analysis of interaction between clopidogrel and proton pump inhibitor therapy. [abstract W1108]. Gastroenterology. 2010;138(5, Suppl 1):S-653.
94. Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy. 2010;30: 275-289.
95. de Aquino L, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med. 2010;8:81.
96. Mistry SD, Trivedi HR, Parmar DM, et al. Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence. Indian J Pharmacol. 2011;43:183-186.
97. Kwok CS, Nijjar RS, Loke YK. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf. 2011;34:47-57.
98. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case-control studies. Am J Med. 1980;68:255-258. (Pubitemid 10168997)
99. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745-754. (Pubitemid 47255992)
100. JAMA evidence. Glossary. http://jamaevidence.com/search/ result/57441 (assessed March 1, 2011).
101. Ziegelin M, Hoschtitzky A, Dunning J, et al. Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Interact Cardiovasc Thorac Surg. 2007;6:534-537. (Pubitemid 47403960)
102. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ DrugSafetyInformationforHeathcare Professionals/ucm079520.htm (assessed March 22, 2011).
103. Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/ Postmarket DrugSafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/PublicHealthAdvisories/ ucm190825.htm (assessed March 22, 2011).
104. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. http://www.fda.gov/Drugs/Drug Safety/ucm231161.htm (assessed March 22, 2011).
105. European Medicines Agency. Public statement March 17, 2010. www.ema.europa.eu/docs/en-GB/document-library/ Public-statement/2010/03/ WC500076346.pdf (assessed Match 1, 2011).
106. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, doubleblind, placebo-controlled trial. Lancet. 2009;374:119-125.
107. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83. (Pubitemid 44306164)
108. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296: 2947-2953. (Pubitemid 46021498)
109. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84:13-19.
110. Corley DA, Kubo A, ZhaoW, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93-101.
111. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951-959.
112. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-326.
113. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896-904.
114. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251-259.
115. de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20: 1989-1998.
116. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170:765-771.
117. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22: 903-910.
118. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209-1218.
119. Ivanovich P, Fellows H, Rich C, et al. The absorption of calcium carbonate. Ann Intern Med. 1967;66:917-923.
120. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70-73. (Pubitemid 15068699)
121. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25:2786-2795.
122. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364-368.
123. DeGrazia JA, Ivanovich P, Fellows H, et al. double isotope method for measurement of intestinal absorption of calcium in man. J Lab Clin Med. 1965;66:822-829.
124. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25:2205-2211.
125. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73:640-647. (Pubitemid 14156843)
126. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376-1380.
127. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005; 118:778-781. (Pubitemid 40897665)
128. Jefferies KC, Cipriano DJ, Forgac Forgac M. Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys. 2008;476:33-42.
129. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop (Belle Mead NJ). 2003;32:222-228.
130. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25:2786-2795.
131. Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48:966-971.
132. Pauh KL, Tan MH. Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures-a case report. Acta Orthop. 2011;82:380-382.
133. Osugi K, Miwa S, Marukawa S, et al. Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy-3 more cases. Acta Orthop. 2011;82:112-113.
134. Ott SM. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2010;33:468.
135. Goddard MS, Reid KR, Johnston JC, et al. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009;32.
136. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355:1834-1836.
137. Broeren MA, Geerdink EA, Vader HL, et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151:755-756.
138. Cundy T, Dissanayake A. Severe hypomagnesaemia in longterm users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69:338-341. (Pubitemid 352009025)
139. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56:112-116.
140. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors: a review. Neth J Med. 2009;67:169-172.
141. Mackay JD, Bladon PT. Hypomagnesaemia due to protonpump inhibitor therapy: a clinical case series. QJM. 2010;103:387-395.
142. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger- Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007;102:2648-2654. (Pubitemid 350179329)
143. Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56:168-174.
144. Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.
145. Administration US FDA. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). 2011; http:// www.fda.gov/Drugs/DrugSafety/ucm245011.htm.
146. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol. 2008;24:230-235. (Pubitemid 351322792)
147. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002;31:166-170.
148. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364-368.
149. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011;27: 180-185.
150. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care. 2008;35:215-237. v-vi. (Pubitemid 351680116)